Shore Capital Partners Announces Partnership with C2Dx and Acquisition of Otolaryngology/Head and Neck Surgery Assets from Cook Medical
Summary
These products provide minimally invasive procedures for ENT surgeons to help treat obstructive salivary disease, chronic ear disorders, nasal/sinus and skull base reconstruction, and dysphagia. Kevin McLeod and his high-caliber team have built an incredible company with an excellent reputation in the medical device space,” said Don Pierce, Partner at Shore and Chairman of the Board of C2Dx. Shore’s strategy is to support management partners to grow faster with less risk, through access to capital, world class board and operational resources, and unmatched networking, development, and shared learnings across the portfolio. From 2020-2023 Shore received recognition from Inc Magazine as a 4x Top Founder Friendly Investor and by Pitchbook research for being the global leader in Private Equity total deal volume. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant potential to grow through industry consolidation and organic growth to generate value for shareholders.